Literature DB >> 10474785

Angiotensin-converting enzyme inhibitors: congestive heart failure and beyond.

W L Lombardi1, S E Litwin.   

Abstract

Angiotensin-converting enzyme (ACE) inhibitors were introduced in the early 1980s as a novel class of agents to treat hypertension. Since that time, they have been proven to be a powerful tool in the treatment of symptomatic left ventricular systolic dysfunction. In this article we will summarize the results from clinical trials using ACE inhibitors in the treatment of heart failure and after myocardial infarction. We will discuss some of the mechanisms postulated to account for the beneficial effects associated with ACE inhibitor treatment. Finally, we will highlight some recent controversies in the use of ACE inhibitors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10474785     DOI: 10.1097/00019501-199909000-00003

Source DB:  PubMed          Journal:  Coron Artery Dis        ISSN: 0954-6928            Impact factor:   1.439


  2 in total

1.  Effects of AT1 receptor antagonist, losartan, on rat hepatic fibrosis induced by CCl(4).

Authors:  Hong-Shan Wei; Ding-Guo Li; Han-Ming Lu; Yu-Tao Zhan; Zhi-Rong Wang; Xin Huang; Jing Zhang; Ji-Lin Cheng; Qin-Fang Xu
Journal:  World J Gastroenterol       Date:  2000-08       Impact factor: 5.742

Review 2.  Pharmacoeconomic considerations in assessing and selecting congestive heart failure therapies.

Authors:  Emile Levy; Pierre Levy
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.